WHWK

Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. (WHWK) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.1
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -34.0%
Price Return 12M 37.2%
Catalyst Signal 0.00
Market Cap $180.6M
TTM Revenue $0.0
Price / Sales N/A
ROE -52.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D+ (1.7) C (2.2) C- (2.0) C+ (2.6) C (2.2)
2026-11-08 A- (3.9) D+ (1.8) C (2.2) C (2.4) C+ (2.6) C+ (2.6)
2026-11-01 B+ (3.7) D+ (1.7) C (2.3) C+ (2.7) C+ (2.7) C+ (2.6)
2026-10-25 B+ (3.7) D+ (1.7) C (2.3) C+ (2.7) C+ (2.6) C+ (2.6)
2026-10-18 B+ (3.7) D+ (1.7) C (2.3) C+ (2.7) C+ (2.6) C+ (2.6)
Page 1 of 4